Objectives: To explore the barriers preventing pioglitazone use in stroke survivors and
primary and secondary stroke care services. Methods: A qualitative grounded theory …

Aims Randomized controlled trials have reported an association between pioglitazone and
reduced incidence of stroke in type 2 diabetic (T2DM) and insulin‐resistant populations. We …

Background Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions.
Recent clinical trials have demonstrated that treatment with pioglitazone reduces …

OBJECTIVE To analyze the effects of pioglitazone in patients with good adherence as well
as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial …

Aim: Prediabetes is an independent risk factor for future stroke. However, no effective
treatment has yet been established for the recurrence of stroke in patients with prediabetes …

Background Patients with ischemic stroke or transient ischemic attack (TIA) are at increased
risk for future cardiovascular events despite current preventive therapies. The identification …

Importance In the Insulin Resistance Intervention After Stroke (IRIS) randomized clinical trial,
pioglitazone, an insulin-sensitizing agent, reduced the risk for recurrent stroke or myocardial …

OBJECTIVE The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that
pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin …

Background and Purpose—Pioglitazone reduced major vascular events after ischemic
stroke in a recent randomized controlled trial. The purpose of this study was to conduct a …

Background and aims: The stroke patients with abnormal glucose metabolism are
increasing in Japan. The J-SPIRIT study (Juntendo the Stroke Prevention study in Insulin …